Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
HRT Financial LP, a ten percent owner of Aditxt, Inc., reported a series of open-market trades in Aditxt common stock over three days in June 2026.
It bought 1,423,493 shares at $0.049 and 725,330 shares at $0.019, while selling 878,659 shares at $0.033, resulting in a net purchase of 1,270,164 shares. Following the most recent trade, HRT Financial LP directly holds 1,040,004 Aditxt common shares.
Aditxt, Inc. disclosed that major shareholders Sandie Gong and spouse Devon Xin Xu reported an open-market sale of 100,000 shares of Common Stock on June 9, 2026 at a weighted average price of $0.0688 per share.
The sale, executed in multiple trades between $0.068 and $0.074, reduced the reported direct holdings for this account to zero shares. The securities were held in a brokerage account of Sandie Gong, with Xu holding trading authorization and being deemed a beneficial owner of the same shares.
Aditxt, Inc. filed an initial ownership report showing that Sandie Gong and Devon Xin Xu are each ten percent owners. The filing reports that 100,000 shares of Common Stock are held in a brokerage account of Sandie Gong. Xu is identified as Gong’s spouse and has trading authorization over the same brokerage account, and may be deemed to beneficially own these reported securities as well. This Form 3 establishes their status as significant shareholders but does not report any new buy or sell transactions.
Aditxt, Inc. disclosed that its wholly owned subsidiary Ignite Proteomics signed a Business Combination Agreement with Copley Acquisition Corp, a special purpose acquisition company, to take Ignite public via a new holding company listed on the NYSE.
The deal values Ignite at an implied equity value of $150,000,000, with Ignite equity holders receiving Pubco common stock based on a $10.00 per share reference price. After closing, Ignite and the SPAC will become wholly owned subsidiaries of Pubco, while Aditxt is expected to remain a separate Nasdaq-listed company holding Ignite’s value through its current ownership.
Aditxt, Inc. disclosed that HRT Financial LP is a significant shareholder in a new Form 3 filing. HRT Financial LP reported direct ownership of 1,193,333 shares of Aditxt common stock. This filing records HRT Financial LP as a more-than-10% beneficial owner, without reporting any new share purchases or sales.
Aditxt, Inc. entered into a new financing arrangement by signing a Note Purchase Agreement with investors and its wholly owned subsidiary, Ignite Proteomics LLC. The parties issued senior secured convertible notes with an aggregate original principal amount tied to $725,000 in cash proceeds plus the outstanding obligations under prior notes, subject to a 35% original issue discount.
Earlier notes with original principal amounts of $3,194,444.44 and $1,250,000 were consolidated into this new series. To secure the notes, Ignite granted a security interest over substantially all of its assets, and Aditxt pledged its equity in Ignite. The notes were sold in a private placement to accredited investors under Section 4(a)(2) and Rule 506(b) of Regulation D.
HRT Financial LP, a ten percent owner of Aditxt, Inc., reported mixed trading in the company’s common stock. On June 4, 2026, it made an open-market purchase of 843,622 shares at $0.076 per share. On June 5, 2026, it executed an open-market sale of 735,462 shares at $0.062 per share. After these transactions, HRT Financial LP reported holding 0 shares of Aditxt common stock directly.
HRT FINANCIAL LP filed an initial Form 3 as a more than ten percent owner of Aditxt, Inc. common stock. The filing reports direct beneficial ownership of 505,302 shares of Common Stock, establishing this baseline position but does not show any recent purchase or sale activity.
Aditxt, Inc. reported the immediate resignations of two key leaders. On June 2, 2026, Christopher J. Porcelli resigned as General Counsel, Chief People Officer and Corporate Secretary, and the Board accepted his resignation the same day. Also on June 2, 2026, Brian Brady resigned as non-executive Chairman of the Board and as a director, effective immediately. The company states that Mr. Brady’s resignation was not due to any disagreement regarding operations, policies, or practices, although he had been chair of the Audit Committee and a member of both the Compensation and Nominating and Corporate Governance Committees.
Aditxt, Inc. announced a major leadership transition, with co-founder Amro Albanna resigning as Chief Executive Officer and director and Rowena Albanna resigning as Chief Operating Officer. Director Shahrokh Shabahang also resigned from the Board but remains Chief Innovation Officer.
The Board appointed Jeffrey M. Busch, age 68, as Interim Chief Executive Officer effective May 31, 2026, and named Brian Brady non-executive Chairman of the Board. Aditxt plans an interim employment arrangement for Mr. Busch that includes a $500,000 annual base salary, with full terms to be disclosed in a later filing.
The company highlighted Mr. Busch’s prior experience founding and leading Global Medical REIT to over $1 billion in enterprise value with an average 8.5% dividend yield, and stated that Aditxt does not currently have a dividend policy or plans to pay dividends.